Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog
about
sameAs
The Camerino symposium series (1978-2013): a privileged observatory of receptorology developmentApproved Antiviral Drugs over the Past 50 YearsThe renaissance of fixed dose combinations: Combivir(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitroThe separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitroSelective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosineActivities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytesMechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidineHigh-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseThe 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptasePharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virusHomologues of isomeric dideoxynucleosides as potential antiviral agents: synthesis of isodideoxynucleosides with a furanethanol sugar moietyGeneration of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidineThe same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidineIncreased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyureaMutagenesis of key residues identifies the connection subdomain of HIV-1 reverse transcriptase as the site of inhibition by heme.Synthesis and antiviral activity of C-5 substituted beta-D- and beta-L-D4T analogues.Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys.High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Tribute to Mark WainbergEquivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily.Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry.Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcriptionPharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development.Antiviral therapy for human immunodeficiency virus infectionsEffect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcriptionEffects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNAStrategies in the treatment of AIDS and related diseases: the lessons of cancer chemotherapy.Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Lamivudine Inhibits the Replication of ALV-J Associated Acutely Transforming Virus and its Helper Virus and Tumor Growth In vitro and In vivo.HIV-1 reverse transcriptase inhibitors.Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection.Lamivudine for the treatment of HIV.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Curious discoveries in antiviral drug development: the role of serendipity.Synthesis of novel L-N-MCd4T as a potent anti-HIV agent.Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.
P2860
Q26830483-4520E933-49E4-427C-A498-C066BD751138Q27755387-A7AD719B-0916-422B-8657-01385AD849A8Q28279752-614C1AA0-6701-4496-8455-24DFDDADD367Q28316326-527A9AFE-73AF-48BB-A6DE-51337383C55CQ28319933-823BD49F-DFBF-4CD0-A9F4-1DBFB2023A52Q28342752-9D23EF0E-4773-46A0-92C5-54EDA02DCA05Q28343244-8DE97543-5608-4EB5-8FCA-50009AD2C5F7Q28367438-4BB093FB-F260-47B6-96CE-D94799F5C8E9Q28367493-A7015915-5492-48B4-8ABA-3335F20F8F5EQ28368054-6DEEAF8F-1516-4264-A871-E333E65BF45BQ28368057-1C216470-695B-45CE-BEA3-765829EC6A06Q28375823-CFE3803C-8E55-4E37-B259-D04C2AF0D0CFQ28378611-6DEBAA5F-AA6A-4615-ACE9-76001600FA7DQ28378626-D030EA79-3DB7-40B1-8530-34CACFE8D104Q28379471-D7A01744-06C8-40E6-B347-BB3AFB2D9F30Q30658869-2C431616-9BD0-4E30-A2AF-63B379D173B1Q31618693-46AD9498-48EF-483E-BD53-7C3534D5B54EQ33703360-E2B05239-6E4E-46CC-9F98-AD6A72876678Q33745246-A8A5243D-6E2D-499E-8F5A-D78AF4379919Q33796791-424B8838-FBD3-4DFE-AD25-83A305D6FDEAQ33846297-C0DF05A1-8F76-4C39-A909-18D4266C9265Q35005426-A1885C34-FA78-4446-BA7A-907725C31E89Q35114114-DDCE9FF5-086D-47F6-A368-2B76D888D5B0Q35122784-B0A4085A-298C-405B-BEAC-87263E3EC0C0Q35125144-950749D9-6B45-4EC1-9216-6571C41FEBFAQ35174403-31FD9CFD-21AA-42D0-9442-450A3572EB4BQ35366050-34DC724B-1554-4531-80FB-3AE5201AED94Q35816131-4416E427-87EB-4B81-A6CE-E01B8BE89280Q35820362-00B2AB63-A9C1-47F0-B4C6-708FC93ABC5DQ35854248-18618A8E-7C3D-4F2C-BC2F-35F15A77BC52Q35930774-64873F36-B979-4741-BD5E-1C831754282CQ36097686-697293A2-4389-42CB-8503-379F6BA32010Q36332936-77471221-EB55-40F5-B524-60C319F2FD6CQ36763644-BAA48FF0-EC29-47D7-94CF-5ABE334C8B25Q37036503-0777191C-F2D3-4BA6-BF58-4A9E8D1BCE6CQ37650410-65FA0DAB-9575-4BC7-88FA-A77DE7ED1A6BQ37859395-64F3D49F-551F-4888-B845-5D7FB9206D11Q38366289-D150E235-8E4D-445D-BD7C-D69CB721D901Q38506878-29003726-98BA-466D-A125-258AF764DF26Q38511971-40869C01-2B11-47E0-A38A-7D455E81A5E7
P2860
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog
description
1991 nî lūn-bûn
@nan
1991 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@ast
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@en
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@nl
type
label
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@ast
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@en
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@nl
prefLabel
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@ast
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@en
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@nl
P2093
P2860
P356
P1476
Anti-human immunodeficiency vi ...... heterocyclic nucleoside analog
@en
P2093
H Soudeyns
M A Wainberg
N Nguyen-Ba
P2860
P304
P356
10.1128/AAC.35.7.1386
P407
P577
1991-07-01T00:00:00Z